Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BNTX Stock Chart & Stats
$94.14
-$4.73(-3.73%)
At close: 4:00 PM EST
$94.14
-$4.73(-3.73%)
Day’s Range― - ―
52-Week Range$81.20 - $129.27
Previous CloseN/A
Volume316.50K
Average Volume (3M)1.37M
Market Cap
$22.16B
Enterprise Value$7.11B
Total Cash (Recent Filing)$14.53B
Total Debt (Recent Filing)$245.40M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Mar 10, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding240,455,440
10 Day Avg. Volume1,400,896
30 Day Avg. Volume1,370,588
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)1.36
Price to Sales (P/S)9.62
P/FCF Ratio-108.15
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit2.73
Enterprise Value/Ebitda-68.81
Forecast
1Y Price Target
$141.93Price Target Upside50.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPhase 2 results for pumitamig + chemo in TNBC patients show promising outcomes, with a 72% overall response rate, which derisks the Phase 3 Rosetta Breast-01 trial.
Oncology PipelineBioNTech remains a promising opportunity based on its substantial war chest, burgeoning pipeline, and plethora of upcoming data releases.
PartnershipsBioNTech's collaboration with Bristol Myers Squibb brings additional credibility and strength to its clinical trials and results.
Bears Say
Market RisksRisks include negative data for various BNT programs, slower-than-expected market uptake, and possible long-term dilution risk.
Regulatory ChallengesThe company now expects to present data and submit the BLA for T-Pam in endometrial cancer in 2026 as they continue to analyze the data and have ongoing discussions with FDA.
Safety ConcernsComprehensive data regarding immune-related toxicities are needed given known autoimmune AEs associated with existing CTLA-4 therapies.
BioNTech SE News
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $81.20 and its highest was $129.27 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $22.16B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Mar 10, 2026 which is in 75 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Nov 03, 2025. The company reported -$0.141 earnings per share for the quarter, beating the consensus estimate of -$1.121 by $0.98.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $2.111 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -0.26.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 240,455,440 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -$0.141 in its last earnings report, beating expectations of -$1.121. Following the earnings report the stock price went up 0.048%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in BNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioNTech SE Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$141.93 (50.76% Upside)
$141.93 (50.76% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.06%
12-Months-Change
Fundamentals
Return on Equity
-2.94%
Trailing 12-Months
Asset Growth
0.30%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a biotechnology company based in Mainz, Germany, focused on developing and manufacturing innovative immunotherapies for the treatment of cancer and other serious diseases. The company specializes in mRNA technology, which has gained significant attention through its development of the Comirnaty COVID-19 vaccine in partnership with Pfizer. BioNTech is also engaged in various therapeutic areas, including oncology, infectious diseases, and rare diseases, working on both individualized and off-the-shelf treatment options.
BNTX Company Deck
BNTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
BioNTech showed strong progress in its oncology programs and financial position, highlighted by increased revenue and strategic advancements. However, challenges include significant financial losses and delays in product submissions due to regulatory discussions.View all BNTX earnings summariesBNTX Stock 12 Month Forecast
Average Price Target
$141.93
▲(50.76% Upside)
Technical Analysis
Ownership Overview
0.36% Insiders
7.23% Mutual Funds
14.02% Other Institutional Investors
77.52% Public Companies and
Individual Investors